Research & Treatment News
May 16, 2012
Two vitamins and a powerful antioxidant may be able to interfere with the acceleration of cellular damage in those with both Hepatitis C and COPD.
Continue reading "Concurrent Hepatitis C and Chronic Obstructive Pulmonary Disease"
Posted by Editors at 10:07 AM
May 7, 2012
In just three weeks, the Hepatitis C drug in development, GS-7977, led to sustained virologic response in over 90 percent of patients when paired with ribavirin and pegylated interferon.
Continue reading "Triple Therapy with GS-7977 Successful Against Hepatitis C"
Posted by Editors at 2:55 PM
May 1, 2012
Of concern to those co-infected with Hepatitis C and HIV, the FDA has confirmed that the Hep C drug, boceprevir, interferes with the HIV drug, ritonavir.
Continue reading "Boceprevir and HIV Drug Can Interact Dangerously"
Posted by Editors at 3:06 PM
April 30, 2012
To assist with drug safety in the presence of Hepatitis C infection, patients are urged to take an active role in managing their medications.
Continue reading "Hep C Bulletin: Medication Management"
Posted by Editors at 10:17 AM
April 24, 2012
Treatment naïve patients with Hepatitis C genotype 1 boasted a 100 percent success rate when given Gilead's GS-7977 and Bristol-Myers Squibb's daclatasvir.
Continue reading "Hep C Trial of Gilead-Bristol Combo Had 100% Success for Genotype 1"
Posted by Editors at 10:32 AM
April 23, 2012
Boehringer Ingelheim's all oral Hepatitis C drugs cured 82 percent of patients with the most common type of Hepatitis C in mid-stage trials. In addition, these drugs exhibited the potential to cure people with cirrhosis.
Continue reading "Trial Claims First All Oral Cure for Advanced Hep C"
Posted by Editors at 4:28 PM